Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.46 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416922 | 0.83 | CDC7 (0.51) | CDC7CYP1A2GRM4TGFBR1MAPT | |
| SCHEMBL4327511 | 0.79 | NPC1 (0.54) | CDC7CYP1A2GRM4TGFBR1MAPT | |
| SCHEMBL30615425 | 0.78 | MAPK1 (0.50) | CDC7CYP1A2GRM4TGFBR1MAPT | |
| SCHEMBL3274399 | 0.76 | CDC7 (0.57) | CDC7CYP1A2GRM4TGFBR1MAPT | |
| SCHEMBL30728059 | 0.75 | CDC7 (0.64) | CDC7CYP1A2GRM4TGFBR1MAPT | |
| SCHEMBL30279147 | 0.74 | CDC7 (0.55) | CDC7CYP1A2GRM4TGFBR1MAPT | |
| SCHEMBL8311439 | 0.74 | CDC7 (0.55) | CDC7CYP1A2GRM4TGFBR1MAPT | |
| SCHEMBL8788646 | 0.74 | CDC7 (0.59) | CDC7CYP1A2GRM4TGFBR1MAPT | |
| SCHEMBL15152227 | 0.74 | CDC7 (0.56) | CDC7CYP1A2GRM4TGFBR1MAPT | |
| SCHEMBL31735411 | 0.73 | BPTF (0.64) | CDC7TRPM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | CDC7 824/4885CYP1A2 3484/4885GRM4 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.